Risk management considerations and advanced therapy medicinal products

被引：0
|
作者：
Ruppert-Seipp, G. [1 ]
Muller, S. [1 ]
Berg, P. [1 ]
Funk, M. B. [1 ]
机构：
[1] Paul Ehrlich Inst, Langen, Germany
来源：
HUMAN GENE THERAPY | 2022年 / 33卷 / 23-24期
关键词：
D O I：
暂无
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
P636
引用
收藏
页码：A194 / A194
页数：1
相关论文
共 50 条
  • [31] Is the Conjunctiva a Potential Target for Advanced Therapy Medicinal Products?
    Diebold, Yolanda
    Garcia-Posadas, Laura
    PHARMACEUTICS, 2021, 13 (08)
  • [32] Advanced therapy medicinal products, the promise of significant progress
    Guerriaud, Mathieu
    ACTUALITES PHARMACEUTIQUES, 2019, 58 (583): : 1 - 1
  • [33] SAFETY VIGILANCE OF ADVANCED THERAPY MEDICINAL PRODUCTS (ATMPS)
    Jimenez-Martin, C. M.
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2011, 109 : 17 - 18
  • [34] European regulatory experience with advanced therapy medicinal products
    Lisbeth Barkholt
    Caroline Voltz-Girolt
    June Raine
    Tomas Salmonson
    Martina Schüssler-Lenz
    Nature Reviews Drug Discovery, 2019, 18 : 8 - 9
  • [35] Advanced Therapy Medicinal Products: What's in a Name?
    Jiskoot, Wim
    JOURNAL OF PHARMACEUTICAL SCIENCES, 2020, 109 (11) : 3282 - 3284
  • [36] Advanced Therapy Medicinal Products and the Changing Role of Academia
    Priesner, Christoph
    Hildebrandt, Martin
    TRANSFUSION MEDICINE AND HEMOTHERAPY, 2022, 49 (03) : 158 - 162
  • [37] European Regulatory Tools for Advanced Therapy Medicinal Products
    Flory, Egbert
    Reinhardt, Jens
    TRANSFUSION MEDICINE AND HEMOTHERAPY, 2013, 40 (06) : 409 - 412
  • [38] Patient access to and ethical considerations of the application of the European Union hospital exemption rule for advanced therapy medicinal products
    Cuende, Natividad
    Ciccocioppo, Rachele
    Forte, Miguel
    Galipeau, Jacques
    Ikonomou, Laertis
    Levine, Bruce L.
    Srivastava, Alok
    Zettler, Patricia J.
    CYTOTHERAPY, 2022, 24 (07) : 686 - 690
  • [39] Requirements for long-term follow-up on efficacy and safety of advanced therapy medicinal products. Risk management and traceability
    Klug, B.
    Reinhardt, J.
    Schroeder, C.
    BUNDESGESUNDHEITSBLATT-GESUNDHEITSFORSCHUNG-GESUNDHEITSSCHUTZ, 2010, 53 (01) : 58 - 62
  • [40] THE FAILURE MODE, EFFECTS AND CRITICALITY ANALYSIS (FMECA) METHOD: A USEFUL APPROACH FOR RISK MANAGEMENT PLAN IN ADVANCED THERAPY MEDICINAL PRODUCTS MANUFACTURING
    Meyer, A.
    Vaquer, G.
    Birebent, B.
    Gautier, E.
    Segier, J-M
    Gouby, J.
    Basch, B.
    Khadri, H.
    Doucet, J.
    Bierling, P.
    Rouard, H.
    CYTOTHERAPY, 2015, 17 (06) : S11 - S11
12345